Brief: Nabriva Therapeutics On Jan 4,2022 Received Notice From Nasdaq Saying Co Is Not In Compliance With Certain Requirement For Continued Listing
07/01/2022 22:14
Jan 7 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS PLC- ON JAN 4, 2022, CO RECEIVED
NOTICE
FROM NASDAQ INDICATING CO IS NOT IN COMPLIANCE WITH MINIMUM BID
PRICE REQUIREMENT FOR CONTINUED LISTING ON THE NASDAQ GLOBAL
SELECT MARKET
Source text for Eikon: ID:
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update